Anton Iliuk
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$8.5MFederal grants as PI16 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
16 awards · $8.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 10, 2026 | NIH | SBIR Phase II Validation and clinicaldevelopment of plasma EV protein biomarkers for minimally-invasive detection of Alzheimersdisease | $747K | TYMORA ANALYTICAL OPERATIONS LLC |
| Aug 5, 2025 | NIH | SBIR Phase II Validation and clinicaldevelopment of plasma EV protein biomarkers for minimally-invasive detection of Alzheimersdisease | $854K | TYMORA ANALYTICAL OPERATIONS LLC |
| Sep 20, 2024 | NIH | SBIR Phase II Validation and clinicaldevelopment of plasma EV protein biomarkers for minimally-invasive detection of Alzheimersdisease | $815K | TYMORA ANALYTICAL OPERATIONS LLC |
| Aug 19, 2022 | NIH | SBIR Phase I Development of lavage EV protein biomarkers for minimally-invasive detection of endometrial cancer | $290K | TYMORA ANALYTICAL OPERATIONS LLC |
| Aug 11, 2021 | NIH | SBIR Phase II Development of non-invasive biomarker discovery and diagnostics approach for bladder cancer based on urine proteome and phosphoproteome | $700K | TYMORA ANALYTICAL OPERATIONS LLC |
| Aug 2, 2021 | NIH | SBIR Phase I Development of companion diagnostics for dasatinib-based personalized therapy for T-ALL | $310K | TYMORA ANALYTICAL OPERATIONS LLC |
| Aug 2, 2021 | NIH | SBIR Phase I Development of companion diagnostics for dasatinib-based personalized therapy for T-ALL | $310K | TYMORA ANALYTICAL OPERATIONS LLC |
| Sep 14, 2020 | NIH | SBIR Phase II Development of non-invasive biomarker discovery and diagnostics approach for bladder cancer based on urine proteome and phosphoproteome | $600K | TYMORA ANALYTICAL OPERATIONS LLC |
| Sep 1, 2020 | NIH | SBIR Phase II Development of non-invasive biomarker discovery and diagnostics approach for bladder cancer based on urine proteome and phosphoproteome | $1.3M | TYMORA ANALYTICAL OPERATIONS LLC |
| Aug 30, 2019 | NIH | SBIR Phase II Development of non-invasive biomarker discovery and diagnostics approach for bladder cancer based on urine proteome and phosphoproteome | $225K | TYMORA ANALYTICAL OPERATIONS LLC |
| Jun 15, 2019 | NIH | SBIR Phase I Development of non-invasive research and diagnostics platform for Alzheimer's disease based on plasma exosomes | $215K | TYMORA ANALYTICAL OPERATIONS LLC |
| Jun 13, 2019 | NIH | SBIR Phase I Development of non-invasive research and diagnostics platform for Alzheimer's disease based on plasma exosomes | $215K | TYMORA ANALYTICAL OPERATIONS LLC |
| Jul 25, 2016 | NIH | SBIR Phase II Multiplexed detection and imaging of protein phosphorylation based on soluble nanopolymers | $446K | TYMORA ANALYTICAL OPERATIONS LLC |
| Aug 25, 2015 | NIH | SBIR Phase I Developing gel-based platform for quantitative phosphoproteomics | $150K | TYMORA ANALYTICAL OPERATIONS LLC |
| Jul 1, 2015 | NIH | SBIR Phase II Multiplexed detection and imaging of protein phosphorylation based on soluble nanopolymers | $452K | TYMORA ANALYTICAL OPERATIONS LLC |
| Jul 1, 2015 | NIH | SBIR Phase II Multiplexed detection and imaging of protein phosphorylation based on soluble nanopolymers | $897K | TYMORA ANALYTICAL OPERATIONS LLC |
Peer ranks
Federal funding#101
Awards as PI#48
Patents#505
Companies
- TYMORA ANALYTICAL OPERATIONS LLCLinked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.